Sana Biotechnology (SANA) Cash from Investing Activities (2020 - 2026)

Sana Biotechnology (SANA) has 7 years of Cash from Investing Activities data on file, last reported at $49.4 million in Q1 2026.

• For the quarter ending Q1 2026, Cash from Investing Activities rose 197.76% year-over-year to $49.4 million; the trailing twelve-month figure through Mar 2026 stood at -$7.4 million (down 106.65% YoY), and the FY2025 full-year result was -$40.2 million, down 330.55% from the prior year.
• Cash from Investing Activities rose to $49.4 million in Q1 2026, from -$16.5 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $88.4 million in Q4 2022 to a low of -$77.2 million in Q1 2024.
• A 5-year average of $24.1 million and a median of $31.9 million in 2022 frame the typical range for Cash from Investing Activities.
• Across the five-year window, Cash from Investing Activities soared 400.02% in 2023 and sank 223.12% in 2024, its largest moves.
• Tracing SANA's Cash from Investing Activities over 5 years: stood at $88.4 million in 2022, then slumped by 82.69% to $15.3 million in 2023, then surged by 207.56% to $47.1 million in 2024, then slumped by 135.03% to -$16.5 million in 2025, then soared by 399.69% to $49.4 million in 2026.
• Business Quant data shows SANA's Cash from Investing Activities at $49.4 million in Q1 2026, -$16.5 million in Q4 2025, and -$48.0 million in Q3 2025.